Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine
CA: A Cancer Journal for Clinicians · 2025
DOI: 10.3322/caac.70007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, 2025. Verfasst von Malik E Juweid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Precision Medicine, Fluorodeoxyglucose F18, Neoplasms, Molecular Imaging. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cancer molecular imaging is the noninvasive visualization of a process unique to or altered in neoplasia, such as proliferation, glucose metabolism, and receptor expression, which is relevant to patient management. Several molecular imaging modalities are now available, including magnetic resonance, optical, and nuclear imaging. Nuclear imaging, particularly using fluorine‐18–fluorodeoxyglucose positron emission tomography, is widely used in the staging and response assessment of multiple cancer types. However, at this writing, new nuclear medicine probes, especially positron emission tomography tracers, are increasingly used or are being investigated for cancer evaluation. This review focuses on these probes, their biologic targets, and the applications or potential applications for their use in the assessment of various neoplasms, including both probes available for commercial use—such as somatostatin receptor ligands in neuroendocrine tumors, prostate‐specific membrane antigen ligands in prostate cancer, norepinephrine analogs in neural crest tumors like neuroblastoma, and estrogen analogs in breast cancer—and others in clinical development, such as fibroblast‐activating protein inhibitors, C‐X‐C chemokine receptor type 4 ligands, and monoclonal antibodies targeting receptor tyrosine kinases, CD4‐positive or CD8‐positive tumor‐infiltrating lymphocytes, tumor‐associated macrophages, and cancer stem cell biomarkers. These developments represent a major step toward the integration of molecular imaging as a powerful tool in precision medicine, with an expectedly significant impact on patient management and outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan.
- The National Center for Diabetes, Endocrinology, and Genetics, University of Jordan, Amman, Jordan.
- Division of Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
- Research and Innovation Department, Antoine Lacassagne Cancer Center, Nice, France.
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
- Medical Imaging Physics (INM-4), Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
ORCID-Profile: Malik E Juweid, Soud F Al-Qasem, Fadlo R Khuri, Andrea Gallamini, Philipp Lohmann, Felix M Mottaghy
Zitieren
APA
Juweid, M. E., Al-Qasem, S. F., Khuri, F. R., Gallamini, A., Lohmann, P., Ziellenbach, H. J., & Mottaghy, F. M. (2025). Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70007
Vancouver
Juweid ME, Al-Qasem SF, Khuri FR, Gallamini A, Lohmann P, Ziellenbach HJ, et al. Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine. CA: A Cancer Journal for Clinicians. 2025. doi:10.3322/caac.70007
BibTeX
@article{Juweid2025,
author = {Juweid, Malik E and Al-Qasem, Soud F and Khuri, Fadlo R and Gallamini, Andrea and Lohmann, Philipp and Ziellenbach, Hans-Joachim and Mottaghy, Felix M},
title = {Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine},
journal = {CA: A Cancer Journal for Clinicians},
year = {2025},
doi = {10.3322/caac.70007}
}
EUVIMED